RESEARCH TRIANGLE PARK, N.C., July 29 /PRNewswire-FirstCall/ -- Icagen,
Inc. (Nasdaq: ICGN) today announced it will release second quarter 2008
financial results on Tuesday, August 5, 2008. The Company will also conduct a
conference call that day at 10:00 a.m. Eastern Time to discuss results and
highlights of the second quarter 2008.
Conference call details:
Date: Tuesday, August 5, 2008
Time: 10:00 a.m. ET
Dial-in (U.S. and Canada): 800-260-8140
Dial-in (International): 617-614-3672
Access code: 21478367
Web cast: www.icagen.com
An archived version of the webcast will also be available on Icagen's
website for at least two weeks following the call. A playback of the call
will be available from approximately 1:00 p.m. Eastern Time on August 5, 2008
for seven days and may be accessed by dialing:
Access number (U.S. and Canada): 888-286-8010
Access number (International): 617-801-6888
Access code: 49878323
About Icagen
Icagen, Inc. is a biopharmaceutical company based in Research Triangle
Park, North Carolina, focused on the discovery, development and
commercialization of novel orally-administered small molecule drugs that
modulate ion channel targets. Utilizing its proprietary know-how and
integrated scientific and drug development capabilities, Icagen has identified
multiple drug candidates that modulate ion channels. The Company is conducting
research and development activities, in some cases in collaboration with
leading pharmaceutical companies, in a number of disease areas, including
epilepsy, pain and inflammation. The Company has clinical stage programs in
epilepsy and asthma.
Forward Looking Statements
This press release contains forward-looking statements that involve a
number of risks and uncertainties. For this purpose, any statements contained
herein that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the words
"believes," "anticipates," "plans," "expects," "intends," and similar
expressions are intended to identify forward-looking statements. Important
factors that could cause actual results to differ materially from the
expectations described in these forward-looking statements are set forth under
the caption "Risk Factors" in the Company's most recent Quarterly Report on
Form 10-Q, filed with the SEC on May 12, 2008. These risk factors include
risks as to the Company's history of net losses and how long the Company will
be able to operate on its existing capital resources; the Company's ability to
raise additional funding; the Company's ability to maintain compliance with
NASDAQ's continued listing requirements; whether the Company's product
candidates will advance in the clinical trials process; the timing of such
clinical trials; whether the results obtained in preliminary studies will be
indicative of results obtained in clinical trials; whether the clinical trial
results will warrant continued product development; whether and when, if at
all, the Company's product candidates, including ICA-105665 and the Company's
other lead compounds for epilepsy and neuropathic pain and senicapoc for
asthma, will receive approval from the U.S. Food and Drug Administration or
equivalent regulatory agencies, and for which indications, and if such product
candidates receive approval, whether such products will be successfully
marketed; and the Company's dependence on third parties, including
manufacturers, suppliers and collaborators. We disclaim any intention or
obligation to update any forward-looking statements as a result of
developments occurring after the date of this press release.
Contacts:
Richard D. Katz, M.D. Gregory Gin
EVP, Finance and Corporate Development; Lazar Partners, Ltd.
Chief Financial Officer
Icagen, Inc.
(919) 941-5206 (212) 867-1762
rkatz@icagen.com ggin@lazarpartners.com
SOURCE Icagen, Inc.